Applied Therapeutics Announces Corporate Updates
Applied Therapeutics (Nasdaq: APLT) announced that its Board has initiated a process to explore strategic alternatives including mergers, acquisitions, partnerships, licensing or other transactions to maximize shareholder value.
The Company said it reduced its workforce by approximately 46% and is implementing other cost‑containment and cash conservation measures to preserve runway. The Board completed a Type C meeting with the FDA on govorestat for CMT‑SORD in Q3 2025 and expects to request an additional Type C to discuss a potential Phase 3 design. The Company also accepted FDA written feedback on govorestat data for Classic Galactosemia and is evaluating next steps. No timetable or assurance of a transaction was provided.
Applied Therapeutics (Nasdaq: APLT) ha annunciato che il Consiglio di Amministrazione ha avviato un processo per esplorare alternative strategiche tra cui fusioni, acquisizioni, partnership, licenze o altre transazioni per massimizzare il valore per gli azionisti.
L'azienda ha dichiarato di aver ridotto la forza lavoro di circa il 46% ed è in corso l'implementazione di ulteriori misure di contenimento dei costi e di conservazione della liquidità per preservare la disponibilità di mezzi. Il Consiglio ha completato un incontro di tipo C con la FDA su govorestat per CMT-SORD nel terzo trimestre 2025 e prevede di richiedere un ulteriore Type C per discutere un potenziale disegno di fase 3. L'azienda ha inoltre accettato il feedback scritto della FDA sui dati di govorestat per la Galattosemia Classica e sta valutando i passi successivi. Nessuna tempistica o garanzia di una transazione è stata fornita.
Applied Therapeutics (Nasdaq: APLT) anunció que su Junta Directiva ha iniciado un proceso para explorar alternativas estratégicas incluyendo fusiones, adquisiciones, asociaciones, licencias u otras transacciones para maximizar el valor para los accionistas.
La compañía dijo que redujo su personal en aproximadamente un 46% y está implementando otras medidas de contención de costos y conservación de efectivo para preservar su runway. La Junta completó una reunión de tipo C con la FDA sobre govorestat para CMT-SORD en el tercer trimestre de 2025 y espera solicitar un nuevo Type C para discutir un posible diseño de fase 3. La Compañía también aceptó comentarios por escrito de la FDA sobre los datos de govorestat para Galactosemia clásica y está evaluando los próximos pasos. No se proporcionó un calendario ni una garantía de una transacción.
Applied Therapeutics (나스닥: APLT)은 이사회가 주주 가치 극대화를 위한 합병, 인수, 파트너십, 라이선스 또는 기타 거래를 포함한 전략적 대안을 모색하는 절차를 시작했다고 발표했습니다.
회사 측은 직원 수를 약 46% 줄였다고 밝히고 현금 보전 및 비용 절감 조치를 추가로 시행하여 운용 자금을 확보하고 있습니다. 이사회는 2025년 3분기에 C형 FDA 회의를 거쳐 CMT-SORD의 govorestat에 대해 논의했고, 3상 설계 가능성에 대해 논의하기 위한 추가 C형 회의를 요청할 예정입니다. 또한 회사는 Classic Galactosemia에 대한 govorestat 데이터에 대한 FDA 서면 피드백를 수용했고 다음 조치를 평가 중입니다. 거래의 일정표나 보장은 제공되지 않았습니다.
Applied Therapeutics (Nasdaq : APLT) a annoncé que son conseil d'administration a entamé un processus pour explorer des alternatives stratégiques incluant des fusions, des acquisitions, des partenariats, des licences ou d'autres transactions afin de maximiser la valeur pour les actionnaires.
L'entreprise a indiqué avoir réduit ses effectifs d'environ 46% et met en œuvre d'autres mesures de maîtrise des coûts et de conservation de la trésorerie pour préserver sa runway. Le conseil a terminé une réunion de type C avec la FDA sur le govorestat pour le CMT-SORD au troisième trimestre 2025 et prévoit de demander une autre Type C pour discuter d'un éventuel design de phase 3. L'entreprise a également accepté les retours écrits de la FDA sur les données de govorestat pour la Galactosemie Classique et évalue les prochaines étapes. Aucun calendrier ni garantie de transaction n'a été fourni.
Applied Therapeutics (Nasdaq: APLT) gab bekannt, dass der Aufsichtsrat einen Prozess eingeleitet hat, um strategische Alternativen zu prüfen, darunter Fusionen, Akquisitionen, Partnerschaften, Lizenzen oder andere Transaktionen, um den Wert für die Aktionäre zu maximieren.
Das Unternehmen sagte, es habe die Belegschaft um etwa 46% reduziert und setzt weitere Kostenkontroll- und Cash-Conservation-Maßnahmen um, um die Liquidität sicherzustellen. Der Vorstand habe im dritten Quartal 2025 ein Type-C-Gespräch mit der FDA zu Govorestat für CMT-SORD geführt und beabsichtigt, einen weiteren Type-C-Termin zu beantragen, um ein potenzielles Phase-3-Design zu besprechen. Das Unternehmen hat außerdem schriftliches Feedback der FDA zu Govorestat-Daten bei Classic Galactosemia akzeptiert und prüft die nächsten Schritte. Kein Zeitplan oder Garantie für eine Transaktion wurde vorgelegt.
Applied Therapeutics (بورصة ناسداك: APLT) أعلنت أن مجلس إدارتها بدأ عملية لاستكشاف بدائل استراتيجية بما في ذلك الاندماجات والاستحواذات والشراكات والتراخيص أو غيرها من المعاملات لتعظيم قيمة المساهمين.
قالت الشركة إنها قلّصت قوتها العاملة بنحو 46% وتنفذ تدابير أخرى للسيطرة على التكاليف وتوفير النقد للحفاظ على المسار المالي. أكمل المجلس اجتماع من النوع C مع الـ FDA حول govorestat لـ CMT-SORD في الربع الثالث من 2025 ويتوقع طلب اجتماع Type C إضافي لمناقشة تصميم محتمل للمرحلة 3. كما قبلت الشركة رد FDA المكتوب على بيانات govorestat لمرض Galactosemia الكلاسيكي وتقييم الخطوات التالية. لم يتم تقديم جدول زمني أو ضمان لصفقة.
- Board initiated formal strategic alternatives review process
- Workforce reduction of approximately 46% to cut expenses
- Completed a Type C FDA meeting for govorestat (CMT‑SORD)
- Accepted FDA written feedback on govorestat Classic Galactosemia data
- No assurance the strategic review will result in any transaction
- No timetable set for completion of the strategic review
- Workforce reduction of approximately 46% may reduce operational capacity
Insights
Board launches strategic review, cuts staff and seeks further FDA clarity on govorestat; timing and outcome remain uncertain.
Applied Therapeutics has initiated a formal review of strategic alternatives while reducing its workforce by
The company is simultaneously reviewing FDA Type C meeting minutes for govorestat in
Key items to watch are the request and outcome of the next Type C meeting, any announced transaction or partnership, and operational runway after workforce reductions; no timetable was provided on
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that Applied Therapeutics’ Board of Directors (the “Board”) has initiated a process to explore strategic alternatives for the Company.
The Board intends to evaluate a broad range of opportunities to maximize shareholder value. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions.
The Board is committed to acting in the best interests of all stockholders. Consistent with its fiduciary duties and responsibilities, the Board will, in consultation with its financial and legal advisors, carefully evaluate and consider all options. The Company has not set a timetable for completion of the process for evaluating strategic alternatives. The Company does not intend to make any further public comment regarding the strategic review process unless and until it determines that further disclosure is appropriate or necessary. There is no assurance that this strategic review will result in a transaction or any other particular outcome.
In connection with the evaluation of strategic alternatives, the Company is reducing the Company’s workforce by approximately
“Our commitment to bringing govorestat to patients with rare diseases remains unwavering. To further advance this mission while maximizing value for shareholders, the Board has initiated a process to explore strategic alternatives designed to preserve our cash runway and ensure that we pursue the optimal path forward for all stakeholders. I want to sincerely thank our dedicated employees for their commitment to Applied, govorestat, patients and caregivers,” said Les Funtleyder, interim CEO and CFO of Applied Therapeutics.
Regulatory Update
As previously announced, the Company completed a Type C meeting with the United States Food and Drug Administration (FDA) regarding govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency (CMT-SORD) in the third quarter of 2025. The Company is evaluating the official Type C meeting minutes and post-meeting written correspondence and expects to submit a request for an additional Type C meeting with the FDA with the intent of further discussing a potential Phase 3 trial design.
Additionally, the Company recently accepted written feedback from the FDA in connection with its planned meeting on the body of govorestat data submitted by the Company for Classic Galactosemia. The Company is evaluating the feedback with its advisors as it assesses next steps for the development of govorestat for the treatment of Classic Galactosemia. The Company may pursue additional discussions with the FDA regarding a potential Phase 3 trial design at a later date.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). To learn more, please visit www.appliedtherapeutics.com and follow the company on X at @Applied_Tx.
Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding the strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “plan,” “intend,” “predicts” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the Company’s business, plans and outlook, (ii) our plans to explore strategic alternatives, including the timing and terms of any potential transaction, and our ability to identify a suitable third party and complete a transaction on acceptable terms, or at all, (iii) our plans to implement a corporate restructuring and workforce reduction, including the timing and scope of these events, and our ability to reduce cash burn as a result of these events, and (iv) expectations about the clinical development, regulatory strategy and commercialization of govorestat, including the potential for an NDA submission in CMT-SORD and potential eligibility for accelerated approval pathway, the timing and outcome of the upcoming meetings and other interactions with the FDA, the timing, design and readouts of our ongoing and clinical trials, including the potential Phase 3 trial in CMT-SORD and any other additional studies or trials that may be required by the FDA, and our development plans in Classic Galactosemia. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.
Such risks and uncertainties include, without limitation, (i) our plans to pursue a strategic transaction and whether any transaction, if pursued, will be completed on attractive terms; (ii) our plans to develop, market and commercialize our product candidates, (iii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iv) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (v) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (vi) our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vii) our ability to maintain and establish collaborations or obtain additional funding, (viii) our ability to obtain and timing of regulatory approval of our current and future product candidates, (ix) the anticipated indications for our product candidates, if approved, (x) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (xi) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, including following our corporate restructuring, (xii) the implementation of our business model and strategic plans for our business and product candidates, (xiii) our intellectual property position and the duration of our patent rights, (xiv) developments or disputes concerning our intellectual property or other proprietary rights, (xv) our expectations regarding government and third-party payor coverage and reimbursement, (xvi) our ability to compete in the markets we serve, (xvii) the impact of government laws and regulations and liabilities thereunder, (xviii) developments relating to our competitors and our industry, (xix) our ability to achieve the anticipated benefits from the agreements entered into in connection with our partnership with Advanz Pharma and (xx) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including those described in the “Risk Factors” section contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Contacts
Investors:
Julie Seidel / Andrew Vulis
(212) 600-1902
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
FAQ
What strategic alternatives is Applied Therapeutics (APLT) exploring as of November 20, 2025?
How many employees is Applied Therapeutics cutting in the November 20, 2025 update?
What is the regulatory status of govorestat for CMT‑SORD mentioned on November 20, 2025?
Did Applied Therapeutics receive FDA feedback on govorestat for Classic Galactosemia?
Will Applied Therapeutics provide a timetable for the strategic review process?
